Article
P53 genotype as a determinant of ER expression and tamoxifen response in the MMTV-Wnt-1 model of mammary carcinogenesis.
Breast cancer research and treatment - 1 Nov 2011
Fuchs-Young Robin, Shirley Stephanie H, Lambertz Isabel, Colby Jennifer K L, Tian Jie, Johnston Dennis, Gimenez-Conti Irma B, Donehower Lawrence A, Conti Claudio J, Hursting Stephen D
Abstract excerpt
Clinical studies show that estrogen receptor-α (ER) expressing tumors tend to have better prognosis, respond to antiestrogen therapy and have wild-type p53. Conversely, tumors with inactivating mutations in p53 tend to have worse outcomes and to be ER-negative and unresponsive to antihormone treatment. Previous studies from our laboratory have shown that p53 regulates ER expression transcriptionally, by binding...
Topics
- Animals
- Antineoplastic Agents, Hormonal
- Cell Transformation, Neoplastic
- Estrogen Receptor alpha
- Female
- Gene Expression
- Genotype
- Heterozygote
- Loss of Heterozygosity
- Mammary Neoplasms, Experimental
- Mice
- Mice, Inbred C57BL